A
Arvinas
Biotech & Life Sciences · New Haven, United States · Founded 2013 · IPO 2018
Pharmaceutical company focused on protein degradation approaches to develop novel drugs to treat cancer and other diseases MoreLess
Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat debilitating and life-threatening diseases. The company operates in the biotechnology sector and primarily serves patients suffering from conditions caused by disease-causing proteins. Arvinas leverages its proprietary technology platform to create proteolysis targeting chimeras (PROTAC® protein degraders), which are designed to harness the body's natural protein disposal system to selectively degrade harmful proteins.
The company's business model revolves around the discovery, development, and commercialization of these novel therapies. Arvinas generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, as well as through the potential commercialization of its own drug candidates.
Arvinas operates in the global biopharmaceutical market, targeting a range of diseases including cancer and neurodegenerative disorders. The company aims to improve patient outcomes by providing targeted, effective treatments that address the underlying causes of these diseases.
Keywords: protein degradation, PROTAC, biopharmaceutical, clinical-stage, biotechnology, disease-causing proteins, innovative therapies, cancer, neurodegenerative disorders, proprietary technology.
Talent graph
Arvinas's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Arvinas has talent and traffic
team presence
across markets
Patent intelligence
$128M patent portfolio · 115 active families
Where Arvinas concentrates vs peers
Each axis is a top-10 topic across Arvinas and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Arvinas
An AI-synthesized read of the highest-engagement posts about Arvinas on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arvinas on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.